Physician profile
Scaria Mathew
NPI 1083623466
$4,252.14
in general payments reported to CMS, 2019-2025
32 companies · $565 in 2025
The $565 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $245 · 2021: $486 · 2022: $822 · 2023: $674 · 2024: $487 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.25 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $737.10 | 2019-2024 | Farxiga, Breztri |
| Abbvie INC. | $623.57 | 2021-2025 | |
| Glaxosmithkline, LLC. | $472.37 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $373.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $328.56 | 2019-2025 | |
| Amgen INC. | $311.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $169.94 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $139.85 | 2019-2020 | |
| Novo Nordisk INC | $126.59 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $119.93 | 2019-2023 | Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $112.73 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.00 | 2019-2025 | Jardiance, Tradjenta |
| Ironwood Pharmaceuticals, INC | $73.80 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.01 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $57.02 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $53.79 | 2022-2023 | Qelbree |
| Esperion Therapeutics, INC. | $47.86 | 2022-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $44.40 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $43.60 | 2021-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $41.52 | 2021-2024 | |
| Mylan Specialty L.P. | $38.88 | 2019-2023 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $25.37 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.65 | 2019 | |
| Shire North American Group INC | $16.11 | 2019 | |
| Amarin Pharma, INC. | $15.04 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.78 | 2025 | Gvoke Hypopen |
| Tactile Systems Technology INC | $14.76 | 2025 | Nimbl, Flexitouch Plus |
| Nestle Healthcare Nutrition INC. | $12.97 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.83 | 2021 | |
| Dynavax Technologies Corporation | $12.27 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scaria Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.